Aim Immunotech Stock Quote 0A4Y - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

Bid

Ask

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

Previous Close

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

48,842,000

Dividend Yield

PE Ratio

-3.04

Earnings Per Share (EPS)

-0.59

Revenue

202k

Net Profit

-28.96M

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.aimimmuno.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Aim Immunotech Inc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker 0A4Y. The last closing price for Aim Immunotech was -. Over the last year, Aim Immunotech shares have traded in a share price range of $ 0.00 to $ 0.00.

Aim Immunotech currently has 48,842,000 shares outstanding. Aim Immunotech has a price to earnings ratio (PE ratio) of -3.04.

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today...

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Next safety cohort to...

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer OCALA, Fla...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Year marked by growing body of promising data demonstrating Ampligen’s potential to address...

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM...

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research Data demonstrate...

AIM ImmunoTech Announces Launch of CEO Corner Platform

AIM ImmunoTech Announces Launch of CEO Corner Platform CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AMIXAutonomix Medical Inc	$ 1.3701 (121.70%)	154.81M
SHOTWSafety Shot Inc	$ 0.41 (115.79%)	7.56k
DATSDatChat Inc	$ 1.89 (81.73%)	54.75M
CYNCYNGN Inc	$ 9.18 (53.77%)	17.79M
SCNIScinai Immunotherapeutics Ltd	$ 5.80 (42.86%)	29.37M
ASLNASLAN Pharmaceuticals Ltd	$ 1.36 (-46.67%)	1.16M
KZIAKazia Therapeutics Ltd	$ 0.5593 (-37.56%)	15.34M
LCFYLocafy Ltd	$ 3.5597 (-36.32%)	584.38k
NAASNaaS Technology Inc	$ 2.82 (-33.02%)	1.94M
ZENVZenvia Inc	$ 1.67 (-26.75%)	658.26k
FFIEFaraday Future Intelligent Electric Inc	$ 0.5152 (22.09%)	217.92M
NVDANVIDIA Corporation	$ 128.44 (-0.62%)	208.32M
SQQQProShares UltraPro Short QQQ	$ 7.46 (-0.67%)	155.14M
AMIXAutonomix Medical Inc	$ 1.3701 (121.70%)	154.81M
TSLATesla Inc	$ 252.64 (1.78%)	147.31M